142 related articles for article (PubMed ID: 22543914)
21. Medical treatment of epithelial ovarian cancer.
González-Martín AJ
Expert Rev Anticancer Ther; 2004 Dec; 4(6):1125-43. PubMed ID: 15606338
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and safety of the combination paclitaxel/carboplatin in patients with previously treated advanced ovarian carcinoma: a multicenter French Groupe des Investigateurs Nationaux pour l'Etude des Cancers Ovariens phase II study.
Pujade-Lauraine E; Guastalla JP; Weber B; Curé H; Orfeuvre H; Mousseau M; Vincent P; Diéras V; Tubiana-Mathieu N; Jacquin JP; Mignot L; Leduc B; Paraïso D; Viens P
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-30-S15-35. PubMed ID: 9346219
[TBL] [Abstract][Full Text] [Related]
23. Bone metastasis as the presenting complaint in ovarian carcinoma.
Kingston R; Sparkes J; Leen E; Stafford-Johnson D; Keogh P
Acta Obstet Gynecol Scand; 2001 Jul; 80(7):669-70. PubMed ID: 11437731
[No Abstract] [Full Text] [Related]
24. Borderline mucinous tumour with mural nodule of signet ring adenocarcinoma.
Ong NC; Ostör AG
Aust N Z J Obstet Gynaecol; 2002 Nov; 42(5):561-2. PubMed ID: 12495115
[No Abstract] [Full Text] [Related]
25. Systemic therapy for ovarian cancer: current status and new treatments.
Ozols RF
Semin Oncol; 2006 Apr; 33(2 Suppl 6):S3-11. PubMed ID: 16716797
[TBL] [Abstract][Full Text] [Related]
26. Skin metastasis of ovarian cancer: a rare entity.
Arslan C; Dede DS; Dizdar O; Altundag K
J BUON; 2010; 15(2):398-9. PubMed ID: 20658746
[No Abstract] [Full Text] [Related]
27. [Activity of paclitaxel, epirubicin and carboplatin in patients with advanced or recurrent endometrial cancer].
Nakashima R; Enomoto T; Murata Y; Fujita M
Nihon Rinsho; 2004 Oct; 62 Suppl 10():360-4. PubMed ID: 15535268
[No Abstract] [Full Text] [Related]
28. [Comparison of pegylated liposomal doxorubicin and carboplatin with paclitaxel and carboplatin in the treatment of patients with late recurrence of platin-sensitive ovarian carcinoma].
Zvaríková M
Klin Onkol; 2011; 24(6):475-6. PubMed ID: 22268244
[No Abstract] [Full Text] [Related]
29. Multimodal approach to ovarian cancer.
Scarfone G; Bolis G
Ann Oncol; 2006 May; 17 Suppl 5():v199-200. PubMed ID: 16807456
[No Abstract] [Full Text] [Related]
30. High Efficacy and Low Toxicity of the Modified Docetaxel and Carboplatin Protocol in Patients with Recurrent Ovarian Cancer-A Phase 2 Cohort Study.
Bruchim I; Weeg N; Alpert Y; Sade D; Piura E; Fishman A
Int J Gynecol Cancer; 2016 May; 26(4):640-7. PubMed ID: 27101523
[TBL] [Abstract][Full Text] [Related]
31. Paclitaxel-induced diffuse cutaneous sclerosis: a case with associated esophageal dysmotility, Raynaud's phenomenon, and myositis.
Winkelmann RR; Yiannias JA; DiCaudo DJ; Trotter SC; Farhey Y; Griffing WL; Martorano LM; Winkelmann JC
Int J Dermatol; 2016 Jan; 55(1):97-100. PubMed ID: 25266415
[No Abstract] [Full Text] [Related]
32. Phase II trial of topotecan, carboplatin, and paclitaxel as front-line therapy in suboptimal advanced epithelial ovarian cancer.
Bolis G; Scarfone G; Villa A; Parazzini F
Gynecol Oncol; 2001 May; 81(2):331-3. PubMed ID: 11330974
[No Abstract] [Full Text] [Related]
33. [A case of metastatic rectal cancer from serous adenocarcinoma of the ovary].
Miyake Y; Kato T; Oshima S; Iijima S; Kurokawa E; Okamoto Y; Kumazawa K; Chin R; Amemiya K; Adachi K; Kikkawa N
Gan To Kagaku Ryoho; 2007 Dec; 34(13):2317-9. PubMed ID: 18079639
[TBL] [Abstract][Full Text] [Related]
34. Comparisons of the survival time of patients with ovarian cancer adopting post-operative chemotherapy by use of paclitaxel combined with carboplatin or nedaplatin.
Gao H; Yuan L; Han Y
World J Surg Oncol; 2016 Jun; 14(1):168. PubMed ID: 27341795
[TBL] [Abstract][Full Text] [Related]
35. Combination chemotherapy of intraperitoneal carboplatin and intravenous paclitaxel in suboptimally debulked epithelial ovarian cancer.
Nagao S; Fujiwara K; Ohishi R; Nakanishi Y; Iwasa N; Shimizu M; Goto T; Shimoya K
Int J Gynecol Cancer; 2008; 18(6):1210-4. PubMed ID: 18284454
[TBL] [Abstract][Full Text] [Related]
36. Progressive epithelial ovarian carcinoma. Prognostic factors and clinical management.
Grønlund B
Dan Med Bull; 2006 Aug; 53(3):232-57. PubMed ID: 17092448
[No Abstract] [Full Text] [Related]
37. Response to salvage treatment in recurrent ovarian cancer treated initially with paclitaxel and platinum-based combination regimens.
Roland PY; Barnes MN; Niwas S; Robertson MW; Alvarez R; Austin JM; Kilgore LC; Partridge EE
Gynecol Oncol; 1998 Feb; 68(2):178-82. PubMed ID: 9514799
[TBL] [Abstract][Full Text] [Related]
38. [Treatment of ovarian cancer].
Cianti C
Clin Ter; 2002; 153(2):135-44. PubMed ID: 12078339
[TBL] [Abstract][Full Text] [Related]
39. Management of platinum-sensitive relapsed ovarian cancer, with particular reference to the International Collaboration in Ovarian Neoplasm-4/Arbeitsgemeinschaft Gynakologische Onkologie Ovarian Cancer-2.2 trial.
Kaye SB
Int J Gynecol Cancer; 2005; 15 Suppl 1():31-5. PubMed ID: 15839956
[TBL] [Abstract][Full Text] [Related]
40. [Study by the Working Group in Gynecologic Oncology for therapeutic optimization in advanced FIGO IIb-IV ovarian carcinoma: cisplatin-paclitaxel vs. carboplatin-paclitaxel. AGO Protocol Ovar-3].
Mettler L
Zentralbl Gynakol; 1996; 118(6):379-4. PubMed ID: 8768017
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
